About
Drug Candidate for Osteoarthritis Therapy
Synovio Therapeutics develops a novel small molecule, Fenchone 1D, a specific agonist to the CB2 receptor as a drug candidate for Osteoarthritis therapy.
Identity
| Name | Synovio Therapeutics |
|---|---|
| Slug | synovio-therapeutics |
| Type / kind | startup |
| Source _id | 2EWFcfscPpAiucsdytAe0GPzFggoB5RwPbk7wQ9P6VnVfRiVGI8wrx |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ address | Israel |
Web & social
| Website | https://synoviotx.com/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2C
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}